Pharmacogenomics

mygeneRx

The study of the relationship between genes and response to drugs has been the subject of intensive research over the past two decades and robust evidence now exists to support testing under clinical conditions.
There is a great deal of variability in how a patient responds to medications due to the genes that govern drug metabolism. Pharmacogenomics empowers the doctor to provide patient-specific medical intervention and replaces the current trial and error approach to drug therapy

A pharmacogenomics test gives insight into how each patient metabolizes, transports, and binds specific prescription drugs, which in turn allows allows physicians to prescribe those compounds that are most likely to prove efficacious, to avoid those that will not, and in many instances to adjust doses to safe yet therapeutic levels.  Such a personalized approach to medicine has the power to produce better results, particularly for individuals whose genetic profile puts them at risk of experiencing either treatment failure or an adverse reaction from a given drug.

Drug Classes

mycardioRx analyses genetic variants linked to the metabolism of:

Cardiovascular Medications

  • Angiotensin II Receptor Antagonists
  • Antianginal Agents
  • Antiarrhythmics
  • Anticoagulants
  • Antiplatelets
  • Beta Blockers
  • Diuretics
  • Statins

mypsychRx analyses genetic variants linked to the metabolism of:

Psychotropic Medications

  • Antiaddictives
  • Anti-ADHD Agents
  • Anticonvulsants
  • Antidementia Agents
  • Antidepressants
  • Antipsychotics
  • ¬†Benzodiazepines
  • Mood Stabilizers

mypainRx analyses genetic variants linked to the metabolism of:

Pain Medications

  • Fibromyalgia Agents
  • Muscle Relaxants
  • NSAIDs
  • Opioids

Patients most likely to benefit from MyGeneRx testing include those:

  • Experiencing side effects to specific medications
  • Not responding to specific medications
  • Requiring doses outside the recommended range
  • Planning to start on a new medication